- Design
- Meta-analysis of 34 randomised trials
- Population
- Patients with CKD-related anaemia treated with HIF-PHIs
- Primary outcome
- VEGF levels and VEGF-related adverse events
- Effect
- VEGF SMD 0.23 (0.07–0.39); oedema log RR 0.22 (0.09–0.35); no cancer, retinopathy or thrombosis signal
A meta-analysis in the Journal of Nephrology (10 October) pooled 34 randomised trials of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), the oral drugs for anaemia in CKD, looking for consequences of HIF-driven VEGF activation.
VEGF levels rose modestly (standardised mean difference 0.23), more in dialysis patients. Peripheral oedema was consistently more frequent. There was no significant association with cancer, diabetic retinopathy or thrombosis over the trials' follow-up.
The theoretical worry with these drugs has been tumour growth and retinal neovascularisation. Short-term trial data do not show them, which is reassuring, but trials were not long enough to exclude slow-developing harms. HIF-PHIs are marketed in India; the practical approach is to watch for oedema, check eyes in diabetic patients, and be cautious in active malignancy until longer data exist.
- Expect a small rise in VEGF, larger in dialysis patients
- Watch for peripheral oedema, the most consistent adverse signal
- No short-term excess of cancer, retinopathy or thrombosis was found
- Be cautious in active malignancy and keep up retinal screening in diabetes
- Long-term safety remains to be established
Why it matters
It addresses the main theoretical safety concern that has limited use of oral anaemia drugs in CKD.
Don't overread it
Trial follow-up is short — absence of cancer or retinal harm is not proof of long-term safety.
The statistics, in plain English
An SMD of 0.23 is a small effect in standard-deviation units. The oedema estimate is a log risk ratio of 0.22, which corresponds to about a 25% relative increase.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free